Declared Dividend • Mar 27
Dividend of HK$0.12 announced Shareholders will receive a dividend of HK$0.12. Ex-date: 23rd June 2026 Payment date: 17th July 2026 Dividend yield will be 1.9%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 26%. Cash payout ratio: 18%. Announcement • Mar 26
AK Medical Holdings Limited announces Annual dividend, payable on July 17, 2026 AK Medical Holdings Limited announced Annual dividend of HKD 0.1180 per share payable on July 17, 2026, ex-date on June 23, 2026 and record date on June 24, 2026. Reported Earnings • Mar 26
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥0.30 (up from CN¥0.24 in FY 2024). Revenue: CN¥1.48b (up 10% from FY 2024). Net income: CN¥339.1m (up 24% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 2.4%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Mar 26
AK Medical Holdings Limited, Annual General Meeting, Jun 17, 2026 AK Medical Holdings Limited, Annual General Meeting, Jun 17, 2026. Announcement • Mar 05
AK Medical Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 AK Medical Holdings Limited announced that they will report fiscal year 2025 results on Mar 25, 2026 Reported Earnings • Oct 05
First half 2025 earnings: EPS in line with expectations, revenues disappoint First half 2025 results: EPS: CN¥0.14 (up from CN¥0.13 in 1H 2024). Revenue: CN¥694.2m (up 5.6% from 1H 2024). Net income: CN¥160.6m (up 15% from 1H 2024). Profit margin: 23% (up from 21% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 29
First half 2025 earnings: EPS in line with expectations, revenues disappoint First half 2025 results: EPS: CN¥0.14 (up from CN¥0.13 in 1H 2024). Revenue: CN¥694.2m (up 5.6% from 1H 2024). Net income: CN¥160.6m (up 15% from 1H 2024). Profit margin: 23% (up from 21% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Aug 02
AK Medical Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025 AK Medical Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025 Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$6.79, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 17% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$6.08 per share. Announcement • Jun 18
Ak Medical Holdings Limited Declares Final Dividend for the Year Ended 31 December 2024 AK Medical Holdings Limited at its AGM held on June 18, 2025 to declared a final dividend of HKD 7.2 cents per ordinary share of the Company for the year ended 31 December 2024. Upcoming Dividend • Jun 16
Upcoming dividend of HK$0.072 per share Eligible shareholders must have bought the stock before 23 June 2025. Payment date: 18 July 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Hong Kong dividend payers (7.5%). Lower than average of industry peers (2.4%). Reported Earnings • Apr 28
Full year 2024 earnings: EPS in line with expectations, revenues disappoint Full year 2024 results: EPS: CN¥0.24 (up from CN¥0.16 in FY 2023). Revenue: CN¥1.35b (up 23% from FY 2023). Net income: CN¥273.9m (up 50% from FY 2023). Profit margin: 20% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Declared Dividend • Mar 28
Dividend of HK$0.072 announced Shareholders will receive a dividend of HK$0.072. Ex-date: 23rd June 2025 Payment date: 18th July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%. Announcement • Mar 11
AK Medical Holdings Limited to Report Fiscal Year 2024 Results on Mar 26, 2025 AK Medical Holdings Limited announced that they will report fiscal year 2024 results on Mar 26, 2025 Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$5.12, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 8.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.47 per share. Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to HK$5.38, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.40 per share. Reported Earnings • Sep 29
First half 2024 earnings: Revenues and EPS in line with analyst expectations First half 2024 results: EPS: CN¥0.13 (up from CN¥0.12 in 1H 2023). Revenue: CN¥657.1m (up 1.3% from 1H 2023). Net income: CN¥139.3m (up 5.0% from 1H 2023). Profit margin: 21% (in line with 1H 2023). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 30
First half 2024 earnings: Revenues and EPS in line with analyst expectations First half 2024 results: EPS: CN¥0.13 (up from CN¥0.12 in 1H 2023). Revenue: CN¥657.1m (up 1.3% from 1H 2023). Net income: CN¥139.3m (up 5.0% from 1H 2023). Profit margin: 21% (in line with 1H 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • Aug 28
AK Medical Holdings Limited Announces Change of Company Secretary, with Effect from 30 August 2024 The board of directors of AK Medical Holdings Limited announced that Ms. Han Yu (‘Ms. Han’) has resigned as: the company secretary of the Company (the ‘Company Secretary’) and an authorised representative of the Company (‘Authorised Representative’) pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘Stock Exchange’) with effect from 30 August 2024 due to her personal matters and other commitments. Ms. Han has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company. The board also announced that Ms. Ma Rongkun (‘Ms. Ma’) has been appointed as the Company Secretary and an Authorised Representative in replacement of Ms. Han with effect from 30 August 2024. Ms. Ma, aged 30, is the investor relations manager of the Group, being primarily responsible for investor relations of the Group since September 2019. Ms. Ma has over 7 years of experience in the finance industry. Prior to joining the Group, Ms. Ma worked as an investor relations manager at Financial PR Group from February 2018 to September 2019. Ms. Ma obtained her bachelor's degree in social sciences from Hong Kong Baptist University in May 2016. Ms. Ma is an associate of the Hong Kong Chartered Governance Institute. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$3.67, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 8x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 53% over the past three years. Announcement • Aug 02
AK Medical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 AK Medical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024 Upcoming Dividend • Jun 17
Upcoming dividend of HK$0.045 per share Eligible shareholders must have bought the stock before 24 June 2024. Payment date: 18 July 2024. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (3.5%). Buy Or Sell Opportunity • May 22
Now 22% undervalued Over the last 90 days, the stock has risen 17% to HK$5.86. The fair value is estimated to be HK$7.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 13%. For the next 3 years, revenue is forecast to grow by 22% per annum. Earnings are also forecast to grow by 26% per annum over the same time period. Buy Or Sell Opportunity • May 07
Now 25% undervalued Over the last 90 days, the stock has risen 12% to HK$5.63. The fair value is estimated to be HK$7.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 13%. For the next 3 years, revenue is forecast to grow by 22% per annum. Earnings are also forecast to grow by 26% per annum over the same time period. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$5.77, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$7.55 per share. Announcement • Apr 19
Eric Wang to Retire as an Independent Non-Executive Director of AK Medical Holdings Limited The Board of AK Medical Holdings Limited announced that Mr. Eric Wang, who is subject to retirement by rotation in the 2024 AGM pursuant to the Articles, will retire as an independent non-executive Director with effect from the date of conclusion of the 2024 AGM due to his desire to devote more time to his other business commitments. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$5.32, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 8x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$7.66 per share. Major Estimate Revision • Apr 02
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥1.61b to CN¥1.43b. EPS estimate fell from CN¥0.286 to CN¥0.24 per share. Net income forecast to grow 48% next year vs 32% growth forecast for Medical Equipment industry in Hong Kong. Consensus price target down from HK$9.57 to HK$8.59. Share price rose 16% to HK$5.32 over the past week. Declared Dividend • Mar 28
Dividend of HK$0.045 announced Shareholders will receive a dividend of HK$0.045. Ex-date: 24th June 2024 Payment date: 18th July 2024 Dividend yield will be 0.9%, which is lower than the industry average of 3.0%. Announcement • Mar 27
AK Medical Holdings Limited, Annual General Meeting, Jun 18, 2024 AK Medical Holdings Limited, Annual General Meeting, Jun 18, 2024. Reported Earnings • Mar 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.16 (down from CN¥0.18 in FY 2022). Revenue: CN¥1.09b (up 4.0% from FY 2022). Net income: CN¥182.1m (down 11% from FY 2022). Profit margin: 17% (down from 20% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 29%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Announcement • Mar 26
AK Medical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 18 July 2024 AK Medical Holdings Limited proposed ordinary final dividend of HKD 0.045 per share for the Year Ended 31 December 2023. Date of shareholders' approval is 18 June 2024. Ex-dividend date is 24 June 2024; Record date is 28 June 2024; Payment date is 18 July 2024. Announcement • Mar 01
AK Medical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 AK Medical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 Announcement • Feb 06
Ak Medical Holdings Limited Obtains the Certification from National Medical Products Administration The board of directors of AK Medical Holdings Limited announced that the Group obtained the certification approving for the change of the metal 3D printing pelvic defect matching prosthesis Class III medical devices registration by the National Medical Products Administration ("NMPA") of the People's Republic of China (the "PRC") on 24 January 2024. The Group obtained the approval for the registration certificate for Class III medical devices, specifically personalized 3D-printed orthopedic implants for pelvic defects, by NMPA on 30 March 2020, which was the first domestically approved 3D-printed titanium alloy orthopedic implants in China. The change of registration complements the Group's product layout across the entire product line of personalized implants for hip joints. The Group will provide a wide range of doctors and patients for personalized and customized acetabular side products based on 3D-printed reconstruction technology, and enhance customized solutions, ushering in a new era of comprehensive 3D-printed customized hip joint reconstruction surgeries. Since obtaining the first certification for 3D-printed orthopedic implants in the PRC in 2015, the Group has dedicated itself to the development of 3D-printed orthopedics technology and product upgrades, established a system solution for 3D-printed titanium alloy orthopedic implants ranging from orthopedic products such as joints, spine, trauma, shoulder, elbow, ankle, and wrists. The Group's metal 3D-printed technology in the field of orthopedics has undergone innovative exploration, overcome technical challenges, and ultimately realized the complete closed-loop process from exploration to standardization, from customized filing to matched registration approval. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to HK$4.55, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 69% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$6.61 per share. Buying Opportunity • Jan 17
Now 27% undervalued after recent price drop Over the last 90 days, the stock is down 27%. The fair value is estimated to be HK$6.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.7% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 55% in 2 years. Earnings is forecast to grow by 71% in the next 2 years. Announcement • Dec 07
AK Medical Holdings Limited Obtains the Certification for Acetabular Component of Hip Prosthesis Class III Medical Devices Approved by the National Medical Products Administration The board of directors of AK Medical Holdings Limited announced that the Company obtained the certification for Acetabular Component of Hip Prosthesis Class III medical devices approved by the National Medical Products Administration of the People's Republic of China on 30 November 2023. 3D-printed titanium alloy orthopedic implants are now widely used in clinical applications and have achieved good clinical application results. However, since titanium alloy is a biologically inert material, it is difficult to form a bioactive bond with the bone tissue after implantation into human bodies. As such, the first generation of 3D-printed titanium alloy Orthopedic implants still require further improvement in their biological functions. Since obtaining the first certification for 3D-printed orthopedic implants in the PRC in 2015, the Group has dedicated itself to the development of 3D-printed orthopedIC technology and product upgrades, and established a technology platform for surface modification for 3D-printed porous titanium alloy implants. Accordingly, the Group has developed 3DACT Bio®? Technology and having such intellectual property rights, introduced bioactive substances such as Ca/P on the surface of porous titanium alloy implants, and developed 3D-printed titanium alloy joint and spine and other products with bioactive functions. The approval of the certification for the Second-generation Acetabular Component of hip Prosthesis with bioactive function realises the development breakthrough of 3D-printed porous titanium steel implants from bioinertness to bioactive functionality, and upgrades from the First-generation 3D-printed porous titanium aluminum alloy implants to a product that enables the bioactive combination with the bone tissue. The Second-generation of 3D-printed orthopaedic implants with bioactive functions based on 3DACT Bio®? technology is a new breakthrough in the Group's continuous research and development of 3D- printed orthopaedic implant technology, realising the upgrade of 3D-printed orthOPaedic implants. Major Estimate Revision • Nov 20
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥1.37b to CN¥1.24b. EPS estimate also fell from CN¥0.24 per share to CN¥0.214 per share. Net income forecast to grow 38% next year vs 21% growth forecast for Medical Equipment industry in Hong Kong. Consensus price target down from HK$9.34 to HK$9.01. Share price fell 12% to HK$6.70 over the past week. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$7.92, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 23x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$6.46 per share. Reported Earnings • Aug 23
First half 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 1H 2022) First half 2023 results: EPS: CN¥0.12 (up from CN¥0.11 in 1H 2022). Revenue: CN¥648.7m (up 22% from 1H 2022). Net income: CN¥132.6m (up 5.2% from 1H 2022). Profit margin: 20% (down from 24% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. New Risk • Aug 23
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to HK$6.30, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 69% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$7.03 per share. Announcement • Aug 01
AK Medical Holdings Limited to Report Q2, 2023 Results on Aug 22, 2023 AK Medical Holdings Limited announced that they will report Q2, 2023 results on Aug 22, 2023 Upcoming Dividend • Jun 14
Upcoming dividend of HK$0.06 per share at 0.8% yield Eligible shareholders must have bought the stock before 21 June 2023. Payment date: 18 July 2023. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Hong Kong dividend payers (7.8%). Lower than average of industry peers (1.7%). Valuation Update With 7 Day Price Move • May 19
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$7.21, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 68% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$6.71 per share. Reported Earnings • Mar 29
Full year 2022 earnings: Revenues in line with analyst expectations Full year 2022 results: Revenue: CN¥1.05b (up 38% from FY 2021). Net income: CN¥204.8m (up 121% from FY 2021). Profit margin: 20% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 31% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Feb 17
AK Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022 AK Medical Holdings Limited provides consolidated earnings guidance for the year ended 31 December 2022. For the period, The company expects to record an increase in revenue by over 35% for the year ended 31 December 2022 as compared to the revenue for the year ended 31 December 2021; and the Board expects to record a significant increase in net profit attributable to Shareholders by over 100% for the year ended 31 December 2022 as compared to the net profit attributable to Shareholders for the year ended 31 December 2021. Announcement • Feb 09
AK Medical Holdings Limited Obtains the Certification for the Dental Implant System Class III Medical Devices Approved by the National Medical Products Administration The board of directors AK Medical Holdings Limited announced that the Company obtained the certification for the dental implant system Class III medical devices approved by the National Medical Products Administration ("NMPA") of the People's Republic of China (the "PRC") on 3 February 2023. The product consists of dental implants and dental implants accessories; the dental implants are available in standard and tapered versions and are made of pure titanium TA4 in accordance with GB/T13810 or ISO5832-2, with its surface being treated by sandblasting and acid etching treatment. Prior to this, in July 2022, the Group obtained the certification for Class III medical devices for bone filling biomaterials for maxillofacial surgery. The approval of these two products marked the Group's entry into the field of oral and maxillofacial prosthetics. In the future, the Group will draw on its successful experience in orthopaedics and rely on its team of dental experts to focus on new technologies and materials and provide new solutions for dental implants. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Eric Wang was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment deteriorated over the past week After last week's 18% share price decline to HK$7.58, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$5.87 per share. Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improved over the past week After last week's 20% share price gain to HK$7.59, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 13x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 7.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$7.56 per share. Reported Earnings • Sep 02
First half 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.10 in 1H 2021) First half 2022 results: EPS: CN¥0.11 (up from CN¥0.10 in 1H 2021). Revenue: CN¥531.2m (up 19% from 1H 2021). Net income: CN¥126.0m (up 13% from 1H 2021). Profit margin: 24% (down from 25% in 1H 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 55%, compared to a 1,300% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment improved over the past week After last week's 17% share price gain to HK$7.03, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$10.76 per share. Major Estimate Revision • Aug 04
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from CN¥0.14 to CN¥0.16. Revenue forecast steady at CN¥1.06b. Net income forecast to grow 89% next year vs 18% growth forecast for Medical Equipment industry in Hong Kong. Consensus price target up from HK$8.13 to HK$8.68. Share price rose 12% to HK$6.99 over the past week. Announcement • Aug 03
AK Medical Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022 AK Medical Holdings Limited announced that they will report first half, 2022 results on Aug 30, 2022 Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment improved over the past week After last week's 25% share price gain to HK$5.98, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 14x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$10.73 per share. Announcement • Jun 16
AK Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021 AK Medical Holdings Limited approved final dividend of HKD 2.5 cents per ordinary share for the year ended 31 December 2021 at its Annual General Meeting held on 15 June 2022. Upcoming Dividend • Jun 10
Upcoming dividend of HK$0.025 per share Eligible shareholders must have bought the stock before 17 June 2022. Payment date: 13 July 2022. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (2.0%). Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 16% share price gain to HK$4.66, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 12x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 20% over the past three years. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Eric Wang was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 
